Celgene Consulting (Shanghai) Co., Ltd.

Primary objective: To determine the proportion of subjects who achieved a ≥33% reduction in transfusion burden (RBC/transfusion) from baseline in any consecutive 24-week interval (from the start of treatment until the last subject completed 48 weeks of treatment) treated with Rotacept + BSC compared with placebo + BSC. Secondary objectives: To evaluate the effects of Rotecept + BSC vs. placebo + BSC on the following indicators: - Reduction in RBC transfusion burden (proportion of subjects with a ≥33%/≥50% reduction in transfusion burden from baseline in any consecutive 12-week interval and defined fixed period; proportion of subjects with a ≥50% reduction in transfusion burden from baseline in any consecutive 24-week interval) - Mean change in transfusion burden from baseline - TI (proportion of subjects transfusion-independent for ≥8/≥12 weeks) - Duration of transfusion burden reduction or TI - Time to transfusion reduction - Frequency of transfusion events - Iron parameters (serum ferritin, liver iron concentration, myocardial iron) and use of iron chelation therapy - HRQoL assessments, including TranQoL and SF-36 - Spleen volume To evaluate the safety of Rotecept compared with placebo in Chinese subjects with β-thalassemia To evaluate the immunogenicity of Rotecept in Chinese subjects with β-thalassemia To evaluate the PK of Rotecept in Chinese subjects with β-thalassemia Exploratory objective: To evaluate the impact of Rotecept on the utilization of medical resources

Primary objectives: To evaluate whether maintenance CC-486 improves relapse-free survival (RFS) compared with placebo in patients with acute myeloid leukemia (AML) who first achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi); Secondary objectives: To determine the effect of maintenance CC-486 compared with placebo on overall survival (OS) in AML subjects who first achieve CR/CRi; To determine the effect of maintenance CC-486 compared with placebo on other efficacy endpoints in AML subjects who first achieve CR/CRi; To assess the safety and tolerability of CC-486 in AML subjects; To characterize the pharmacokinetics of CC-486 in AML subjects; To evaluate the prognostic and therapeutic significance of residual disease in the bone marrow; To determine the effect of maintenance CC-486 compared with placebo on health-related quality of life (HRQoL) and healthcare resource utilization

This retrospective and prospective, non-interventional, multicenter study will evaluate the safety and efficacy of azacitidine (AZA) in patients with intermediate-risk-2 (Int-2) and high-risk myelodysplastic syndrome (MDS) (determined by IPSS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% bone marrow (BM) blasts and multilineage dysplasia (determined by WHO classification) treated with the Chinese product label under routine medical practice conditions in real-world settings (including inpatient and outpatient settings).